Navigation Links
African-American women with advanced breast cancer often forego vital treatment
Date:5/21/2009

A new study finds that nearly one in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, potentially life saving therapies. Published in the July 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that more efforts are needed to ensure that all women with breast cancer receive appropriate care.

In the United States, African American women have almost twice the rate of advanced (stage III) breast cancer than white women. To get a better sense of the tumor characteristics and medical care of these patients, researchers led by Monica Rizzo, M.D., of the Emory University School of Medicine and Emory University's Avon Comprehensive Breast Cancer Center at Grady reviewed stage III breast cancer data from 2000 to 2006 from an inner city hospital in Atlanta that serves a large African American population.

The investigators identified 107 cases of stage III breast cancers diagnosed and/or treated at this hospital over the six years of study. Approximately 87 percent of these cases were in African American women. Triple negative tumors accounted for 29 percent of the cases. These cancers do not express the estrogen receptor, the progesterone receptor or the human epidermal growth factor receptor 2 (HER2) and therefore do not respond well to therapies that target these proteins (such as trastuzumab, or Herceptin, which blocks HER2).

Chemotherapy and radiation are recommended therapies for patients with stage III breast cancer; however many women in this study decided to forego these treatments. The study found 20.5 percent of patients with stage III breast cancer refused chemotherapy, and 26.3 percent who should have received chest radiation refused. There was no difference in marital status, religious background, or age of the patients who refused either chemotherapy or radiation compared with the patients who received recommended care.'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. African-American women still have poorer breast cancer outcomes
2. High blood pressure linked to earlier death among African-American breast cancer patients
3. PSA levels accurately predict prostate cancer risk in African-American men
4. Grammy-nominated Singer Angie Stone Encourages African-Americans in Birmingham to Fearlessly FACE Diabetes
5. Hormone linked to high blood pressure and blood vessel disease in African-Americans
6. Childrens Hospital study finds African-Americans more distrusting of research than whites
7. African-Americans have worse prognosis at colorectal cancer diagnosis
8. Outdoor alcohol advertising and problem drinking among African-American women in NYC
9. Gay and bisexual African-American men have the lowest use of prostate testing
10. Birthing Project USA Unites to Reduce the African-American Infant Mortality Rate: Pilgrimage to Babyland
11. Church effort sharply increases first-time African-American blood donors
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan 2Health News:Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan 3Health News:Expanding Patient Population Creates a Huge Market for Invasive Pressure Monitoring and Hemodynamic Monitoring, Finds Frost & Sullivan 4Health News:LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees 2Health News:Al Copeland Foundation Signs on as Title Sponsor of 2009 Chris Paul Basketball Camp 2Health News:Al Copeland Foundation Signs on as Title Sponsor of 2009 Chris Paul Basketball Camp 3Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 2Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 3Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 4Health News:Thomson Reuters Announces 100 Top Hospitals Award Winners 5Health News:A Star-Filled Evening with The AFA's Illuminations Los Angeles 2Health News:A Star-Filled Evening with The AFA's Illuminations Los Angeles 3Health News:Dr. Rudy Kachmann, Neurosurgeon, Author, Lecturer & Founder of Kachmann Mind Body Institute Selects TransMedia Group as Agency of Record 2
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3HealthFitness Announces Third Quarter 2009 Financial Results 60712 1HealthFitness Announces Third Quarter 2009 Financial Results 60712 2HealthFitness Announces Third Quarter 2009 Financial Results 60712 3HealthFitness Announces Third Quarter 2009 Financial Results 60712 4HealthFitness Announces Third Quarter 2009 Financial Results 60712 5HealthFitness Announces Third Quarter 2009 Financial Results 60712 6HealthFitness Announces Third Quarter 2009 Financial Results 60712 7HealthFitness Announces Third Quarter 2009 Financial Results 60712 8HealthFitness Announces Third Quarter 2009 Financial Results 60712 9HealthFitness Announces Third Quarter 2009 Financial Results 60712 10HealthFitness Announces Third Quarter 2009 Financial Results 60712 11Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 1Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 2Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 3Zyngenia Inc Raises 2410 Million in Series A Funding 14724 1Zyngenia Inc Raises 2410 Million in Series A Funding 14724 2Zyngenia Inc Raises 2410 Million in Series A Funding 14724 3Zyngenia Inc Raises 2410 Million in Series A Funding 14724 4